Retrospective Observational Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Patients With BMI>25 kg/m^2, in Real World Clinical Setting
Phase of Trial: Phase IV
Latest Information Update: 23 Jan 2019
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Johnson & Johnson
- 14 Jan 2019 Planned primary completion date changed from 30 Nov 2018 to 29 Mar 2019.
- 16 Nov 2018 Planned End Date changed from 30 Nov 2018 to 29 Mar 2019.
- 11 Oct 2018 Status changed from not yet recruiting to recruiting.